Department of Pathology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Department of Pathology, Mount Sinai Morningside and West Hospitals, New York, NY 10019, USA.
Curr Oncol. 2024 Mar 19;31(3):1556-1561. doi: 10.3390/curroncol31030118.
Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most frequently as a mixed tumor combined with acinar adenocarcinoma. Although the histopathological features of DAP are well known, its genomic characteristics are still evolving, prompting the suggestion that all DAP would benefit from molecular analysis with the purpose of improving tumor recognition, genetic classification, and, ultimately, personalized therapy. Herein, we report a case of DAP with novel genetic alterations (BCOR P1153S, ERG M219I, KDR A750E, POLE S1896P, and RAD21 T461del).
前列腺导管腺癌(DAP)是一种罕见的前列腺癌变异型,与侵袭性疾病和不良预后相关。它最常表现为混合性肿瘤,与腺泡腺癌混合存在。尽管 DAP 的组织病理学特征众所周知,但它的基因组特征仍在不断发展,这促使人们提出建议,即所有 DAP 都将受益于分子分析,以提高肿瘤识别、遗传分类,并最终实现个体化治疗。在此,我们报告一例具有新型遗传改变的 DAP(BCOR P1153S、ERG M219I、KDR A750E、POLE S1896P 和 RAD21 T461del)。